Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Furie

Rheumatology New Hyde Park, NY Medical Doctor

NPI 1538175740 CMS profile 69643

2800 Marcus Ave, Suite 200, New Hyde Park, NY 11042

Open in the dashboard

General payments

$745,820

534 records reported · program years 2019–2025

Research payments

$40,465

Paid to them · 32 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,550,262 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Richard Furie of New Hyde Park, NY is reported in the CMS Open Payments database as having received $745,820 across 534 general payments and $40,465 in research payments paid to them. Separately, studies naming them as principal investigator received $3,550,262 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $123,687 83
2025 Research $8,137 11
2024 General $135,030 115
2024 Research $4,264 5
2023 General $98,605 88
2023 Research $1,292 1
2022 General $127,111 74
2022 Research $1,844 1
2021 General $66,443 37
2020 General $76,594 42
2020 Research $13,158 7
2019 General $118,348 95
2019 Research $11,771 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Furie
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Richard Furie were reported at $123,687. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Richard Furie Rheumatology median Middle half National median
2019 $118,348 $744 $153–$2,687 $163
2020 $76,594 $462 $98–$2,027 $114
2021 $66,443 $531 $101–$2,153 $132
2022 $127,111 $627 $125–$2,303 $149
2023 $98,605 $741 $145–$2,524 $160
2024 $135,030 $830 $166–$2,660 $164
2025 $123,687 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $212,164 138 payments
  2. E.R. Squibb & Sons, L.L.C. $66,778 58 payments
  3. GlaxoSmithKline, LLC. $66,302 42 payments
  4. AstraZeneca UK Limited $63,612 40 payments
  5. Alexion Pharmaceuticals, Inc. $37,860 36 payments
  6. Eli Lilly and Company $34,790 25 payments
  7. Genentech, Inc. $33,109 20 payments
  8. F. Hoffmann-La Roche AG $31,016 16 payments
  9. Chugai Pharmaceutical Co., Ltd. $25,878 11 payments
  10. Biogen, Inc. $23,319 15 payments
  11. Other $150,992 133 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $514,698 230 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $105,871 62 payments
  3. Travel and Lodging $95,431 123 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $11,080 2 payments
  5. Food and Beverage $6,455 107 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $5,133 2 payments
  7. Grant $4,146 2 payments
  8. Honoraria $2,000 1 payment
  9. Education $1,007 5 payments
Products named General payments · program years 2019–2025
  1. SAPHNELO $158,641 122 payments
  2. BENLYSTA $22,374 14 payments
  3. GAZYVA $19,085 14 payments
  4. ULTOMIRIS $17,140 22 payments
  5. NO PRODUCT DISCUSSED $14,298 11 payments
  6. CellCept $10,042 7 payments
  7. ORENCIA $9,975 13 payments
  8. SOLIRIS $8,181 3 payments
  9. NUCALA $4,740 7 payments
  10. Tavneos $4,500 1 payment
  11. Other $15,107 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $14,199 19 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $7,719 2 payments
  3. UCB, Inc. $5,600 2 payments
  4. Biogen, Inc. $5,536 1 payment
  5. AbbVie, Inc. $3,353 4 payments
  6. Eli Lilly and Company $2,215 3 payments
  7. EMD Serono, Inc. $1,844 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,038

Median for Rheumatology: 1,511

Drug cost

$493,932

Median for Rheumatology: $1,139,948

Branded share of claims

27.5%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 35 $211,188
Humira(Cf) Pen Adalimumab Brand 13 $136,316
Enbrel Sureclick Etanercept Brand 17 $119,330
Mycophenolate Mofetil Generic 59 $8,682
Hydroxychloroquine Sulfate Generic 165 $6,025
Methotrexate Methotrexate Sodium Brand 129 $3,863
Prednisone Generic 154 $1,280
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 47 $969
Nifedipine Er Nifedipine Brand 18 $700
Warfarin Sodium Generic 38 $676

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$5,044,972

Of which drugs: $4,865,602

Medicare patients

475

Average age 71

Services billed

228,975

352 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 59%
Osteoporosis 53%
Ischemic heart disease 28%
Diabetes 26%
Chronic kidney disease 23%
Depression 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 28 45,000 $786,119
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 Office 15 10,681 $373,978
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 40 14,290 $354,301
Injection, belatacept, 1 mg J0485 Office 19 80,000 $234,336
Injection, zoledronic acid, 1 mg J3489 Office 175 875 $3,850
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 16 489 $111

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $38,868
  • AstraZeneca UK Limited $12,464
$51,332 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $8,063
$8,063 — —
BENLYSTA
  • GlaxoSmithKline, LLC. $4,276
$4,276 — —
GAZYVA
  • Genentech, Inc. $1,150
$1,150 — —
TREMFYA
  • Janssen Biotech, Inc. $115
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

566 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record